ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma

• Jennifer S. Carew,

  Affiliation Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas, United States of America

  ⨯
• Juan A. Esquivel II,

  Affiliation Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas, United States of America

  ⨯
• Claudia M. Espitia,

  Affiliation Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas, United States of America

  ⨯
• Christoph M. Schultes,

  Affiliation Elara Pharmaceuticals GmbH, Heidelberg, Germany

  ⨯
• Marcel Mülbaier,

  Affiliation Elara Pharmaceuticals GmbH, Heidelberg, Germany

  ⨯
• Joe D. Lewis,

  Affiliation Elara Pharmaceuticals GmbH, Heidelberg, Germany

  ⨯
• Bernd Janssen,

  Affiliation Elara Pharmaceuticals GmbH, Heidelberg, Germany

  ⨯
• Francis J. Giles,

  Affiliation Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas, United States of America

  ⨯
• Steffan T. Nawrocki

  * E-mail: Nawrocki@uthscsa.edu

  Affiliation Department of Medicine and Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas, United States of America

  ⨯